{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T11:36:50Z","timestamp":1773056210203,"version":"3.50.1"},"reference-count":40,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T00:00:00Z","timestamp":1772841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Thrombocytopenia subsequent to antineoplastic therapies leads to bleeding complications, treatment delay or de-intensification, and platelet transfusion requirement. Evidence suggests that thrombopoietin receptor agonists (TPO-RAs) can restore platelet counts in this scenario. Avatrombopag (AVA) is an oral TPO-RA whose efficacy in treating thrombocytopenia in haematological malignancy has been barely addressed. We aimed to evaluate AVA\u2019s efficacy in improving platelet recovery and reducing transfusion requirement in haematological patients with thrombocytopenia. Methods: In this retrospective observational study, haematological patients who developed thrombocytopenia persisting for \u22653 weeks and were treated with AVA between November 2023 and December 2024 were recruited. Results: Twenty-three patients were recruited. Nineteen (82.6%) responded to AVA, most within the first 4 weeks: 10 (43.5%) and 9 (39.1%) achieved platelet counts \u2265 30 \u00d7 109\/L (partial response) and \u2265100 \u00d7 109\/L (complete response), respectively. Response was always maintained for 30 days after AVA withdrawal. Transfusions were significantly fewer than in the previous period: 0 (0\u20138) vs. 11 (2\u201315), median (interquartile range [IQR]), p = 0.007. Once on treatment, 13 (56.5%) patients no longer required transfusion. No patient delayed or de-intensified chemotherapy. No safety concerns were reported. Conclusions: AVA shows promise in safely reducing thrombocytopenia-associated transfusion needs in haematological malignancy.<\/jats:p>","DOI":"10.3390\/jcm15052044","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:58:45Z","timestamp":1773046725000},"page":"2044","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Avatrombopag Reduces Platelet Transfusion Requirement in Thrombocytopenia Subsequent to Antineoplastic Therapies in Haematological Patients: The Experience of a Tertiary Centre"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2598-3299","authenticated-orcid":false,"given":"Aser","family":"Alonso-Carballo","sequence":"first","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3716-6325","authenticated-orcid":false,"given":"Marta","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Garc\u00eda-Ma\u00f1\u00f3","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Mar\u00eda","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9929-8617","authenticated-orcid":false,"given":"Leyre","family":"Bento","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s","family":"Novo","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2708-0090","authenticated-orcid":false,"given":"Albert","family":"P\u00e9rez","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Ballester","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9062-077X","authenticated-orcid":false,"given":"Antonio","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiomar","family":"Puget","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernat","family":"Galm\u00e9s","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palomero","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Sampol","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2875-9292","authenticated-orcid":false,"given":"Mariana","family":"Canaro","sequence":"additional","affiliation":[{"name":"Haematology and Haemotherapy Service, Son Espases University Hospital, 07120 Palma, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,7]]},"reference":[{"key":"ref_1","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015","journal-title":"Oncology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12672-023-00616-3","article-title":"Chemotherapy-induced thrombocytopenia: Literature review","volume":"14","author":"Gao","year":"2023","journal-title":"Discov. Oncol."},{"key":"ref_3","unstructured":"U.S. Department of Health and Human Services (2025, October 23). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17474086.2021.1924053","article-title":"Clinical challenges and promising therapies for chemotherapy-induced thrombocytopenia","volume":"14","author":"Soff","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"101139","DOI":"10.1016\/j.blre.2023.101139","article-title":"Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists","volume":"63","year":"2024","journal-title":"Blood Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1001\/jamaoncol.2016.2466","article-title":"Different Platelet Count Thresholds to Guide Use of Prophylactic Platelet Transfusions for Patients with Hematological Disorders After Myelosuppressive Chemotherapy or Stem Cell Transplantation","volume":"2","author":"Estcourt","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jtha.2023.09.031","article-title":"Management of chemotherapy-induced thrombocytopenia: Guidance from the ISTH Subcommittee on Hemostasis and Malignancy","volume":"22","author":"Soff","year":"2024","journal-title":"J. Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/17474086.2023.2201428","article-title":"Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia","volume":"16","author":"Song","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s40265-018-0949-8","article-title":"Avatrombopag: First global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/17512433.2019.1649137","article-title":"Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease","volume":"12","author":"Xu","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102980","DOI":"10.1016\/j.rpth.2025.102980","article-title":"Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?","volume":"9","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s40265-021-01613-y","article-title":"Avatrombopag: A Review in Thrombocytopenia","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101361","DOI":"10.1016\/j.blre.2025.101361","article-title":"Avatrombopag in immune thrombocytopenia and beyond: Current evidence and emerging perspectives","volume":"28","author":"Lozano","year":"2025","journal-title":"Blood Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1016\/S2352-3026(22)00001-1","article-title":"Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: An international, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Safina","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1080\/09537104.2022.2026910","article-title":"Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors","volume":"33","author":"Gao","year":"2022","journal-title":"Platelets"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/bjh.19797","article-title":"Avatrombopag for the treatment of patients with chemotherapy-induced thrombocytopenia: A case series","volume":"206","author":"Galamaga","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Cui, Y., He, Y., Hu, C., Tu, C., Huang, J., Zhu, X., Zang, C., Ding, K., Zhan, B., and Zhao, Y. (2022). Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.970978"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12957-025-03659-8","article-title":"Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors","volume":"23","author":"Hu","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zhu, L., Liu, J., Kong, P., Gao, S., Wang, L., Liu, H., Zhang, C., Gao, L., Feng, Y., and Chen, T. (2022). Analysis of the efficacy and safety of avatrombopag combined with MSCs for the treatment of thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.910893"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ruan, Y., Cao, W., Luo, T., Liu, X., Liu, Q., Xiao, Y., Wu, C., Xie, D., Ren, Y., and Wu, X. (2023). Avatrombopag for the treatment of thrombocytopenia in children\u2019s patients following allogeneic hematopoietic stem-cell transplantation: A pilot study. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1099372"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20406207221127532","DOI":"10.1177\/20406207221127532","article-title":"Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation","volume":"13","author":"Zhou","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"20406207241304300","DOI":"10.1177\/20406207241304300","article-title":"Efficacy and safety of avatrombopag in the treatment of chemotherapy-induced thrombocytopenia in children with acute lymphoblastic leukemia: A single-center retrospective study","volume":"15","author":"Yang","year":"2024","journal-title":"Ther. Adv. Hematol."},{"key":"ref_23","first-page":"100472","article-title":"Avatrombopag for severe refractory thrombocytopenia in a pediatric patient with ALL following allogeneic hematopoietic stem cell transplantation: A case report","volume":"22","author":"Lynch","year":"2024","journal-title":"Leuk. Res. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/bloodadvances.2022008066","article-title":"Prolonged thrombocytopenia after CAR T-cell therapy: The role of thrombopoietin receptor agonists","volume":"7","author":"Drillet","year":"2023","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/10781552231219003","article-title":"Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis","volume":"31","author":"Gurumurthy","year":"2025","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_26","unstructured":"National Comprehensive Cancer Network (2022). Hematopoietic Growth Factors. NCCN Guidelines Version 1.2022, National Comprehensive Cancer Network. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/ejh.14395","article-title":"Avatrombopag for the Treatment of Immune Thrombocytopenia","volume":"114","author":"Labanca","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"ref_28","first-page":"CD010984","article-title":"Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation","volume":"2015","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(13)60650-9","article-title":"Concepts of blood transfusion in adults","volume":"381","author":"Goodnough","year":"2013","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2025.7529","article-title":"Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines","volume":"334","author":"Metcalf","year":"2025","journal-title":"JAMA"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e099153","DOI":"10.1136\/bmjopen-2025-099153","article-title":"Relationship between thromboembolic events and thrombopoietin receptor agonists: A pharmacovigilance analysis of the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report","volume":"15","author":"Huang","year":"2025","journal-title":"BMJ Open"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Soff, G.A., Ray-Coquard, I., Rivera, L.J.M., Fryzek, J., Mullins, M., Bylsma, L.C., and Park, J.K. (2022). Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0257673"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e7429","DOI":"10.1002\/cam4.7429","article-title":"Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature","volume":"13","author":"Soff","year":"2024","journal-title":"Cancer Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhu, Q., Yang, S., Zeng, W., Li, M., Guan, Z., Zhou, L., Wang, H., Liu, Y., Gao, Y., and Qiu, S. (2021). A Real-World Observation of Eltrombopag and Recombinant Human Thrombopoietin (rhTPO) in Lymphoma Patients with Chemotherapy Induced Thrombocytopenia. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.701539"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"107484","DOI":"10.1016\/j.leukres.2024.107484","article-title":"Eltrombopag treatment in thrombocytopenia following hematopoietic stem cell transplantation: A multicenter real-world experience","volume":"140","author":"Gunes","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_36","first-page":"1148","article-title":"A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies","volume":"106","author":"Parnes","year":"2021","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Joffe, E., Epstein-Peterson, Z., Falchi, L., Noy, A., Zelenetz, A.D., Owens, C., Gilbert, L., Salles, G., and Soff, G.A. (2026). Romiplostim for Prevention of Severe Chemotherapy-Induced Thrombocytopenia in Lymphoma Patients-Phase I Study. Cancers, 18.","DOI":"10.3390\/cancers18020188"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/bloodadvances.2022007838","article-title":"Open-label pilot study of romiplostim for thrombocytopenia after autologous hematopoietic cell transplantation","volume":"7","author":"Scordo","year":"2023","journal-title":"Blood Adv."},{"key":"ref_39","first-page":"106","article-title":"Thrombocytopenia after Hematopoietic Stem Cell Transplantation in Pediatrics and Adults: A Narrative Review Including Etiology, Management, Monitoring, and Novel Therapies","volume":"52","author":"Kalantari","year":"2025","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ajh.26113","article-title":"Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies","volume":"96","author":"Nagle","year":"2021","journal-title":"Am. J. Hematol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/2044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:23:08Z","timestamp":1773048188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/5\/2044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,7]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15052044"],"URL":"https:\/\/doi.org\/10.3390\/jcm15052044","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,7]]}}}